Treatment strategies for patients with concurrent blunt cerebrovascular and traumatic brain injury

医学 创伤性脑损伤 迟钝的 冲程(发动机) 抗血小板药物 外科 内科学 阿司匹林 氯吡格雷 机械工程 精神科 工程类
作者
Javier Figueroa,Katherine Berry,James V. Boddu,Michael Kader,Michael Silva,Evan Luther,Verónica Crisóstomo,Robert M. Starke,Jonathan Jagid,Ronald J. Benveniste
出处
期刊:Journal of Clinical Neuroscience [Elsevier]
卷期号:88: 243-250 被引量:13
标识
DOI:10.1016/j.jocn.2021.03.044
摘要

Patients who present with traumatic brain injury (TBI) combined with blunt cerebrovascular injuries (BCVI) are difficult to manage, in part because treatment for each entity may exacerbate the other. It is necessary to develop a treatment paradigm that ensures maximum benefit while mitigating the opposing risks. A cohort of 150 patients from 2015 to present, with either internal carotid artery (ICA) and/or vertebral artery (VA) dissections or pseudoaneurysms, was cross-referenced with those who had sustained TBI. Of the 38 patients identified with both TBI and BCVI, 25 suffered ICA injuries, 10 had VA injuries and 3 had combined ICA/VA injuries. Unilateral BCVI occurred in 30 patients, while 8 had bilateral BCVI. Two patients required surgical intervention for TBI, and 5 patients required endovascular intervention for BCVI. Positive emboli detection studies (EDS) on transcranial dopplers (TCD) were demonstrated in 19 patients, with 9 patients having radiographic evidence of stroke. Anti-platelet therapy was initiated in 32 patients, and anti-coagulation in 10 patients, without new or worsening intracranial hemorrhages (ICH). Overall, 76% of patients were able to be discharged home or to rehabilitation, with good recovery demonstrated in 73% of the patients who had appropriate follow-up. In the setting of concurrent TBI and BCVI, use of anti-platelet/coagulation to prevent stroke can be safe if monitored closely. Here we describe a treatment paradigm which weighs the risk and benefits of therapies based on severity of ICH and stroke prevention, which tended to result in good disposition and recovery.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
从容灭绝应助chai采纳,获得10
1秒前
2秒前
轻松的芯完成签到 ,获得积分10
3秒前
小白完成签到,获得积分10
4秒前
情怀应助王楠采纳,获得10
5秒前
starry发布了新的文献求助10
5秒前
yueyueyahoo发布了新的文献求助20
5秒前
6秒前
JamesPei应助只只采纳,获得10
7秒前
8秒前
顾难摧完成签到 ,获得积分10
9秒前
9秒前
科研通AI2S应助机灵柚子采纳,获得10
10秒前
12秒前
周周发布了新的文献求助10
14秒前
bifasci完成签到,获得积分10
15秒前
snowwwwwwwwfox完成签到,获得积分10
15秒前
务实的凝天完成签到,获得积分10
15秒前
15秒前
甜美香之完成签到 ,获得积分10
16秒前
丁静完成签到 ,获得积分10
16秒前
11111m发布了新的文献求助10
17秒前
yueyueyahoo完成签到,获得积分10
17秒前
Lucas应助坚持看完采纳,获得10
18秒前
20秒前
starry完成签到,获得积分10
21秒前
赘婿应助wang采纳,获得10
23秒前
24秒前
XH完成签到,获得积分10
25秒前
只只发布了新的文献求助10
26秒前
电致阿光完成签到,获得积分10
26秒前
L21完成签到,获得积分10
26秒前
zhentg完成签到,获得积分0
26秒前
烂漫的煎饼完成签到 ,获得积分10
29秒前
Zz完成签到 ,获得积分10
29秒前
JOY完成签到 ,获得积分10
31秒前
32秒前
乐乐应助L21采纳,获得10
32秒前
浮空鱼发布了新的文献求助10
33秒前
wang发布了新的文献求助10
36秒前
高分求助中
The ACS Guide to Scholarly Communication 2500
Sustainability in Tides Chemistry 2000
Pharmacogenomics: Applications to Patient Care, Third Edition 1000
Studien zur Ideengeschichte der Gesetzgebung 1000
TM 5-855-1(Fundamentals of protective design for conventional weapons) 1000
Genera Insectorum: Mantodea, Fam. Mantidæ, Subfam. Hymenopodinæ (Classic Reprint) 800
Ethnicities: Media, Health, and Coping 700
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3086063
求助须知:如何正确求助?哪些是违规求助? 2738975
关于积分的说明 7552581
捐赠科研通 2388790
什么是DOI,文献DOI怎么找? 1266693
科研通“疑难数据库(出版商)”最低求助积分说明 613547
版权声明 598591